Glycorex Transplantation AB: Geert Nygaard appointed as new CEO

Report this content

Glycorex Transplantation AB can announce that Geert Nygaard has been appointed as Chief Executive Officer of the company and will begin serving in that role on December 15th, 2021.

Geert brings over 30 years of experience in the diagnostics and life science markets from a variety of senior leadership roles with Abbott Laboratories, TECAN, Epigenomics and DAKO. After more than 20 years working abroad and extensive experience working as a CEO internationally, Geert decided to move back to Denmark. Geert has a strong commercial background supported by regulatory and quality expertise. Geert brings experience in leading a publicly listed company and getting FDA approval in the US. Geert has also experience working with antibodies and their applications as well as working with new products within blood transfusion.

“We are happy to welcome Geert”, said Kurt Nilsson, Chairman of Glycorex Transplantation’s Board of Directors. “His background and experience make him well suited to expand and guide the company through its important next phase, that is planning and conducting a clinical study in the U.S., commercializing our UBP-product and obtaining a CE-mark for our RA-product".

Johan Nilsson, Interim CEO, Glycorex Transplantation AB.
E-mail:, phone: 046-286 52 30

This information is such information that Glycorex Transplantation AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on November 2, 2021 at 16.35 CET.

Brief information about the company
Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.


Documents & Links